Hemorrhagic events are the most frequently reported complications during extracorporeal membrane oxygenation (ECMO). Anticoagulation, and in particular, unfractionated heparin (UFH), is commonly used and is often monitored by the activated partial thromboplastin time (aPTT).
Methods:
A retrospective single-center analysis of adult patients undergoing venovenous (VV) ECMO between June 2018 and August 2021 was performed (n = 43). The primary aim of this study was to compare aPTT values with major bleeding events or complications in patients receiving VV-ECMO.
Results:
Bleeding complications were observed in 16 (37%) of patients. The mean heparin dose was significantly higher in the bleeding group versus non- bleeding group for the aPTT target ranges of 40–60 s (12.7 ± 8.07 vs 7.82 ± 2.65 IU/kg/h, p = 0.004) and 63–83 s (12.6 ± 5.78 vs 9.06 ± 4.71 IU/kg/h, p = 0.0002). When comparing bleeding versus nonbleeding groups, there was no difference in the mean aPTT for all aPTT target ranges. In the aPTT 40–60 s range group, the mean aPTT 24 h prior to a bleeding event was 63.2 ± 18.6 s, higher than the set target range.
Conclusions:
In patients undergoing VV-ECMO, major bleeding events did not equate to higher aPTT levels. However, higher mean heparin doses were associated with higher hemorrhagic complications. Our findings suggest that lower aPTT levels may be reasonable to prevent bleeding events.
GerkeAKTangFCavanaughJE, et al. Increased trend in extracorporeal membrane oxygenation use by adults in the United States since 2007. BMC Res Notes2015; 8: 686.
2.
ChengRHachamovitchRKittlesonM, et al. Complications of extracorporeal membrane oxygenation for treatment of cardiogenic shock and cardiac arrest: a meta-analysis of 1,866 adult patients. Ann Thorac Surg2014; 97(2): 610–616.
3.
WillersASwolJKowalewskiM, et al. Extracorporeal life support in hemorrhagic conditions: a systematic review. ASAIO J2021; 67(5): 476–484.
4.
BrodieDSlutskyASCombesA.Extracorporeal life support for adults with respiratory failure and related indications: a review. JAMA2019; 322(6): 557–568.
5.
PopugaevKABakharevSAKiselevKV, et al. Clinical and pathophysiologic aspects of ECMO-associated hemorrhagic complications. PLoS One2020; 15(10): e0240117.
6.
ZangrilloALandoniGBiondi-ZoccaiG, et al. A meta-analysis of complications and mortality of extracorporeal membrane oxygenation. Crit Care Resusc2013; 15(3): 172–178.
7.
DoyleAJHuntBJ.Current understanding of how extracorporeal membrane oxygenators activate haemostasis and other blood components. Front Med2018; 5: 352.
8.
SklarMCSyELequierL, et al. Anticoagulation practices during venovenous extracorporeal membrane oxygenation for respiratory failure. A systematic review. Ann Am Thorac Soc2016; 13(12): 2242–2250.
9.
SilvettiSKosterAPappalardoF.Do we need heparin coating for extracorporeal membrane oxygenation? New concepts and controversial positions about coating surfaces of extracorporeal circuits. Artif Organs2015; 39(2): 176–179.
10.
NunezJIGoslingAFO’GaraB, et al. Bleeding and thrombotic events in adults supported with venovenous extracorporeal membrane oxygenation: an ELSO registry analysis. Intensive Care Med2022; 48(2): 213–224.
11.
SunJ.Comparison of anticoagulation monitoring strategies for adults supported on extracorporeal membrane oxygenation: a systematic review. Heart Lung2023; 61: 72–83.
12.
NguyenTPPhanXTHuynhDQ, et al. Monitoring unfractionated heparin in adult patients undergoing extracorporeal membrane oxygenation (ECMO): ACT, APTT, or ANTI-XA?. Crit Care Res Pract2021; 2021: 5579936.
13.
McMichaelABVRyersonLMRatanoD, et al. 2021 ELSO adult and pediatric anticoagulation guidelines. ASAIO J2022; 68(3): 303–310.
14.
ChlebowskiMMBaltagiSCarlsonM, et al. Clinical controversies in anticoagulation monitoring and antithrombin supplementation for ECMO. Crit Care2020; 24: 19.
15.
KanjiRVandenbrieleCArachchillageDRJ, et al. Optimal tests to minimise bleeding and ischaemic complications in patients on extracorporeal membrane oxygenation. Thromb Haemost2022; 122(4): 480–491.
16.
ChenJChenGZhaoW, et al. Anticoagulation strategies in patients with extracorporeal membrane oxygenation: a network meta-analysis and systematic review. Pharmacotherapy2023; 43(10): 1084–1093.
17.
GraboyesSDTOwenPSEvansRA, et al. Review of anticoagulation considerations in extracorporeal membrane oxygenation support. Pharmacotherapy2023; 43(12): 1339–1363.
18.
TaylorFTohCHHootsK, et al. Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation. Thromb Haemost2001; 86(11): 1327–1330.
19.
PanigadaMArtoniAPassamontiSM, et al. Hemostasis changes during veno-venous extracorporeal membrane oxygenation for respiratory support in adults. Minerva Anestesiol2016; 82(2): 170–179.
20.
AubronCDePuydtJBelonF, et al. Predictive factors of bleeding events in adults undergoing extracorporeal membrane oxygenation. Ann Intensive Care2016; 6: 97.
21.
ArnoukSAltshulerDLewisTC, et al. Evaluation of anti-Xa and activated partial thromboplastin time monitoring of heparin in adult patients receiving extracorporeal membrane oxygenation support. ASAIO J2020; 66(3): 300–306.
22.
CartwrightBBruceHMKershawG, et al. Hemostasis, coagulation and thrombin in venoarterial and venovenous extracorporeal membrane oxygenation: the HECTIC study. Sci Rep2021; 11(1): 7975.
23.
AppeltHPhilippAMuellerT, et al. Factors associated with hemolysis during extracorporeal membrane oxygenation (ECMO)-Comparison of VA- versus VV ECMO. PLoS One2020; 15(1): e0227793.
24.
LyuLYaoJGaoG, et al. Incidence, risk factors, and outcomes of hyperbilirubinemia in adult cardiac patients supported by veno-arterial ECMO. Artif Organs2018; 42(2): 148–154.
25.
RajsicSBreitkopfROezpekerUC, et al. The role of excessive anticoagulation and missing hyperinflammation in ECMO-associated bleeding. J Clin Med2022; 11(9): 2314.
26.
Oude Lansink-HartgringAde VriesAJDrooghJM, et al. Hemorrhagic complications during extracorporeal membrane oxygenation—the role of anticoagulation and platelets. J Crit Care2019; 54: 239–243.
27.
ArachchillageDRJPassarielloMLaffanM, et al. Intracranial hemorrhage and early mortality in patients receiving extracorporeal membrane oxygenation for severe respiratory failure. Semin Thromb Hemost2018; 44(3): 276–286.
28.
MartucciGGianiMSchmidtM, et al. Anticoagulation and bleeding during veno-venous extracorporeal membrane oxygenation: insights from the PROTECMO study. Am J Respir Crit Care Med2024; 209(4): 417–426.
29.
VaquerSde HaroCPerugaP, et al. Systematic review and meta-analysis of complications and mortality of veno-venous extracorporeal membrane oxygenation for refractory acute respiratory distress syndrome. Ann Intensive Care2017; 7(1): 51.
30.
KawauchiALiuKNakamuraM, et al. Risk factors for bleeding complications during venovenous extracorporeal membrane oxygenation as a bridge to recovery. Artif Organs2022; 46(9): 1901–1911.
31.
DelmasCJacqueminAVardon-BounesF, et al. Anticoagulation monitoring under ECMO support: a comparative study between the activated coagulation time and the anti-Xa activity assay. J Intensive Care Med2020; 35(7): 679–686.
32.
ProcacciniDERoemJNgDK, et al. Evaluation of acquired antithrombin deficiency in paediatric patients supported on extracorporeal membrane oxygenation. Br J Clin Pharmacol2023; 89(8): 2396–2406.
33.
AubronCChapalainXBaileyM, et al. Anti-factor-Xa and activated partial thromboplastin time concordance and outcomes in adults undergoing extracorporeal membrane oxygenation: a secondary analysis of the pilot low-dose heparin in critically ill patients undergoing extracorporeal membrane oxygenation randomized trial. Crit Care Explor2023; 5(11): e0999.
34.
NaglerBStaudingerTSchellongowskiP, et al. Incidence of heparin resistance and heparin failure in patients receiving extracorporeal membrane oxygenation: an exploratory retrospective analysis. J Thromb Haemost2024; 22(10): 2773–2783.
35.
HlaTTWChristouSSandersonB, et al. Anti-Xa assay monitoring improves the precision of anticoagulation in venovenous extracorporeal membrane oxygenation. ASAIO J2024; 70(4): 313–320.
36.
DescampsRMoussaMDBesnierE, et al. Anti-Xa activity and hemorrhagic events under extracorporeal membrane oxygenation (ECMO): a multicenter cohort study. Crit Care2021; 25(1): 127.
37.
RanucciMCotzaMIsgròG, et al. Anti-factor Xa-based anticoagulation during extracorporeal membrane oxygenation: potential problems and possible solutions. Semin Thromb Hemost2020; 46(4): 419–427.
38.
KostousovVNguyenKHundalaniSG, et al. The influence of free hemoglobin and bilirubin on heparin monitoring by activated partial thromboplastin time and anti-Xa assay. Arch Pathol Lab Med2014; 138(11): 1503–1506.
39.
MazzeffiMGreenwoodJTanakaK, et al. Bleeding, transfusion, and mortality on extracorporeal life support: ECLS working group on thrombosis and hemostasis. Ann Thorac Surg2016; 101(2): 682–689.
40.
KreyerSMudersTTheuerkaufN, et al. Hemorrhage under veno-venous extracorporeal membrane oxygenation in acute respiratory distress syndrome patients: a retrospective data analysis. J Thorac Dis2017; 9(12): 5017–5029.
41.
RajsicSBreitkopfRTremlB, et al. Association of anti-factor Xa-guided anticoagulation with hemorrhage during ECMO support: a systematic review and meta-analysis. Clin Cardiol2024; 47(5): e24273.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
